On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.

On the news front, AbbVie announced a planned acquisition of Apogee for approximately USD 10.9 billion, with the core asset being APG777, a long-acting IL-13 monoclonal antibody targeting atopic dermatitis (AD). The transaction is expected to close in Q3. The deal reflects multinational pharmaceutical companies' strong endorsement of the strategic value and peak sales potential of long-acting AD assets.

CanNova's pipeline product CM512 belongs to the same long-acting AD track. Analysts note that if clinical data supports extended dosing intervals, the long-acting advantage could significantly enhance its market competitiveness. Additionally, the company's core commercialized product Kangyueda has been approved for multiple indications and included in national medical insurance, with commercial scale-up progressing steadily. The medical sector showed resilience on the day, with capital focusing on innovative drug names accelerating commercialization ahead of Q2 earnings expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)